Transforming growth factor-β stimulates nerve growth factor production in osteoarthritic synovium

Shotaro Takano, Kentaro Uchida, Makoto Itakura, Dai Iwase, Jun Aikawa, Gen Inoue, Manabu Mukai, Masayuki Miyagi, Kosuke Murata, Hiroyuki Sekiguchi and Masashi Takaso

Abstract

Background: Nerve growth factor (NGF) contributes to pain in knee osteoarthritis (KOA) patients. Transforming growth factor-beta (TGF-β) stimulates NGF expression in chondrocytes from KOA patients. However, the correlation between synovial TGF-β and NGF levels has not been sufficiently studied in human KOA patients. Further, the mechanism governing NGF regulation by TGF-β in synovial cells is unclear.

Methods: During total knee arthroplasty, we extracted the synovial tissue (SYT) of 107 subjects with unilateral Kellgren/Lawrence grade 3–4 KOA confirmed by radiography. We examined the distribution of TGF-β and NGF using immunohistochemistry, and analyzed the relationship between NGF and TGFβ mRNA levels. Cultured synovial cells extracted from SYT were exposed to culture medium (control), human recombinant TGF-β (rhTGF-β), rhTGF-β + ALK5 inhibitor SB505124, rhTGF-β + transforming growth factor activating kinase 1 (TAK1) inhibitor (5Z)-7-oxozeaenol, or rhTGF-β + p38 inhibitor SB203580 for 30 min, 6 h and 24 h. NGF mRNA expressed by the cultured cells and NGF protein levels in the cell supernatant were detected by real-time polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay (ELISA), respectively. Phosphorylation of p38 was evaluated by western blotting.

Results: NGF mRNA levels were positively correlated with those of TGFβ. Cells expressing TGF-β and NGF protein were observed in the lining layer of SYT. TGF-β stimulated increased NGF mRNA expression and NGF protein production. The ALK5 inhibitor completely suppressed the TGF-β-mediated increase in NGF expression and NGF production in synovial cells. ALK5, TAK1 and p38 inhibitors inhibited the TGF-β-induced phosphorylation of p38, and TAK1 and p38 inhibitors partially inhibited the TGF-β-mediated increase in NGF expression and NGF production in synovial cells.

Conclusion: TGF-β regulates NGF production via the TGF-β/ALK5 signaling pathway in osteoarthritic synovium. This effect may partially occur through inhibition of the TAK1/p38 pathway in the SYT of KOA patients.

Keywords: Transforming growth factor-β, Nerve growth factor, Osteoarthritis, Synovium
Background
Knee osteoarthritis (KOA) is a common form of joint disease and a leading cause of disability and pain. Its symptoms include pain and reduced mobility, which reduce patients’ quality of life [1]. Pharmacological treatments are generally aimed at relieving pain and improving joint function. However, therapies like non-steroidal anti-inflammatory drugs (NSAIDs) have limited efficacy, and are associated with serious adverse effects including renal, cardiovascular, gastrointestinal, and cardiovascular complications [2]. Understanding the pathways that govern pain in KOA patients may lead to improved drug treatments.

Nerve growth factor (NGF) is a neurotrophin that modulates nociception. It is elevated in chronic pain conditions, leading to increased perception of pain [3]. A recent clinical trial showed that neutralizing NGF was more effective than placebo and NSAIDs for reducing KOA pain [4–7]. Numerous studies have shown that NGF is regulated by inflammatory cytokines, including tumor necrosis factor (TNF)-α and interleukin (IL)-1β, in mouse and human articular chondrocytes, synovial fibroblasts, and synovial macrophages in vitro [8–11]. Synovial tissue (SYT) is a major component of joint inflammation. Interestingly, less inflammation has been observed in the synovium of late stage than early stage OA patients [12]. NGF neutralization reduces pain in both inflammatory and non-inflammatory states [13]. Therefore, synovial NGF regulation under non- or moderate synovial inflammatory states may play an important role in OA, particularly in the late stages of the disease. However, synovial NGF regulation under non- or moderate-inflammatory states is not fully understood.

Several studies have reported that anti-inflammatory cytokines such as transforming growth factor (TGF)-β and IL-10 regulate NGF. Recombinant IL-10 stimulates NGF in astrocytes in vitro [14]. However, studies have found no evidence of an elevation in IL-10 in the synovial fluid or serum of OA patients [15, 16]. In contrast, several clinical studies have shown that the TGF-β is elevated in the synovial fluid of KOA patients [17, 18]. Moreover, a recent study showed that TGF-β stimulated NGF mRNA expression in osteoarthritic articular cartilage in vitro, suggesting that TGF-β may contribute to pain in non-inflammatory OA [19]. These findings suggest that TGF-β may be one of the key molecules involved in NGF regulation in OA. However, the relationship between NGF and TGF-β expression in the osteoarthritic synovium is not fully understood.

In the canonical TGF-β signaling pathway, signaling is started by the binding of three TGF-β isoforms to the type II receptor (TβRII), and the subsequent phosphorylation of the type I receptor (TβRI) [20]. The phosphorylated TβRII, typically ALK5, can then transduce the TGF-β signal intracellularly to phosphorylate R-Smads. In contrast, the non-canonical TGF-β pathway signals through a non-Smad pathway via TGF-β-activated kinase 1 (TAK1), a member of the mitogen-activated protein kinase (MAPK) kinase kinase (MAPKK-K) family, which activates p38 and Jun N-terminal kinase (JNK) and the p38 MAPK pathway. Previous studies have shown that TGF-β regulates NGF mRNA expression via both the canonical and non-canonical pathway [19, 21]. The ALK5 inhibitor SB505124 completely blocked TGF-β-mediated NGF mRNA expression and partially suppressed the action of the TAK1 inhibitor 5Z 8-oxozeanol in osteoarthritic cartilage. However, the effect of the canonical and non-canonical TGF-β pathways on NGF production in the osteoarthritic synovium is not fully understood.

Here, we investigated the mechanism governing the regulation of NGF by TGF-β via the canonical and non-canonical pathways in osteoarthritic synovium.

Methods
Patients
Ethics approval was obtained from the Institutional Review Board (IRB) for Clinical Research and Treatment of Kitasato University (IRB approval number: B13–113). The study sample size was decided by power analysis, with α = 0.05 and power = 0.95, using G*POWER3. The analysis demonstrated that 107 SYT samples were required to identify a statistically significant correlation between TGFβ and NGF mRNA expression.

SYT samples were extracted during total knee replacement surgery from 115 patients with KOA of unilateral Kellgren/Lawrence grades 3 (49/115) and 4 (66/115) confirmed by radiography. Among these, 25 were men and 90 were women. The mean ± standard error (SE) age and body mass index (BMI) was 73.2 ± 0.7 years and 26.1 ± 0.4 kg/m², respectively. Informed consent to participate in this study was obtained from all patients the day prior to surgery.

SYT samples were extracted from the suprapatellar pouch of the operated knee of each patient and immediately transferred to liquid nitrogen before storage in a freezer at −80°C until use for RNA extraction. SYT samples extracted from 24 patients were reserved for cell culture, while the remaining samples were fixed in 4% paraformaldehyde phosphate-buffered solution (Fuji Photo Film Co., Tokyo, Japan) for 48 h for histology.

Quantitative real time polymerase chain reaction (qRT-PCR)
Total RNA extraction from SYT and cultured SYT cells and cDNA synthesis were performed according to a previously described method [22]. The following PCR primer pair sequences were used for qRT-PCR: TGFβ (product size: 91 bp), TGFβ-Forward (5′-CGAC
TCGCCAGAGTGTTAT-3') and TGFβ-Reverse (5'-GCTAAGGCGAAGCCCTCAA-3'); NGF (product size: 74 bp), NGF-Forward (5’-CCCATCCCTCTTCACAGG-3') and NGF-Reverse (5’-GGTGGTCTTATCCCCAACCC-3'); TNFA (product size: 118 bp), TNFA-Forward (5’-CTTCTGCTGTCACCTTTG-3') and TNFA-Reverse (5’-GTACCTGTCGCTGTTGA-3') and IL-1β (product size: 153 bp), IL-1β-Forward (5’-GTACCTGTCGCTGTTGA-3') and IL-1β-reverse (5’-GGAACGTGCCAGACTGAAA-3'); and GAPDH (product size: 223 bp), GAPDH-Forward (5’-TGTTGCATCAATGACCCCTT-3') and GAPDH-Reverse (5’-CTCACGACGTACTCAGCG-3'). Relative TGFβ and NGF expression was evaluated using CFX-96® (Bio-Rad, Richmond CA, USA). TGFβ and NGF mRNA levels were normalized to those of the housekeeping gene, GAPDH.

Immunohistochemistry
To determine the localization of TGF-β and NGF protein, parafomraldehyde-fixed SYT was embedded in paraffin and cut into 4-μm-thick sections using a microtome (n = 10). The sections were deparaffinized in the xylene substitute Neo-Clear (Merck KGaA, Darmstadt, Germany) for 1 h, and subsequently hydrated in a series of decreasing ethanol concentrations (100, 95, and 70%) before rinsing in distilled water. The sections were subjected to antigen retrieval by submerging in sodium citrate buffer (10 mM sodium citrate acid, 0.05% Tween 20, pH 6.0) at 98 °C for 45 min. The sections were cooled to room temperature (RT) and exposed to 3% hydrogen peroxide in methanol for 20 min at RT to block endogenous peroxidases. The sections were rinsed with phosphate-buffered saline (PBS; 3 times, 10 min each) and incubated with 10% goat serum (Nichirei, Tokyo, Japan) at RT, followed by mouse monoclonal primary antibody against TGF-β (cat no. 27969, Abcam, Cambridge, UK) or rabbit polyclonal primary antibody against NGF (cat no. ab6199, Abcam) for 1 h at RT. The sections were rinsed with PBS (3 times, 10 min each) and incubated with biotinylated anti-rabbit IgG (Nichirei) for 10 min at RT. The sections were again rinsed with PBS (3 times, 10 min each) and then incubated with horseradish peroxidase (HRP)-conjugated streptavidin for 10 min. After rinsing with PBS (3 times, 10 min each), the sections were reacted with 3,3’-diaminobenzidine, rinsed in water, then counterstained with Mayer’s hematoxylin and mounted in mounting medium. Negative control mouse and rabbit IgG antibodies were used as negative controls for the mouse monoclonal antibodies and rabbit polyclonal antibodies. No positive cells were observed in the negative control sections.

Cell culture
SYT was digested with 30 mL of 1 mg/ml collagenase solution, and synovial cells were isolated and then cultured (1 x 10^5 cells/cm^2) in α-minimal essential media (MEM) and 10% fetal bovine serum in six-well plates. The medium was changed twice across a 7-day incubation. To identify the synovial cell populations in culture, the cells were incubated with fluorescein isothiocyanate (FITC)-conjugated anti-CD45 (pan leukocyte marker), allophycocyanin (APC)-conjugated anti-CD90 (synovial fibroblast marker), and phycoerythrin (PE)-conjugated anti-CD14 (macrophage marker) antibodies. The fibroblast (CD45-CD90+) and macrophage fractions (CD45 + CD14+) were examined using flow cytometry (FACSVerse™; BD Biosciences, San Jose, CA, USA). We used isotype controls to set the positive gate.

Subsequently, cells derived from 8 patients were exposed to culture medium (control), 10 ng/mL rhTGF-β, or 10 ng/mL rhTGF-β + 5 μM SB505124 for 30 min, 6 h or 24 h. Cells derived from another 8 patients were exposed to culture medium (control), 10 ng/mL human recombinant TGF-β (rhTGF-β), or 10 ng/mL rhTGF-β + 1 μM 5Z-7-oxozeaenol (5Z) for 30 min, 6 h or 24 h. Cells derived from the remaining 8 patients were exposed to culture medium (control), 10 ng/mL rhTGF-β, or 10 ng/mL rhTGF-β + 1 μM SB203580 for 30 min, 6 h or 24 h. After stimulation for 30 min, p38 phosphorylation was evaluated by western blotting to monitor the effect of inhibitors on the non-canonical pathway. After stimulation for 6 and 24 h, total RNA was extracted from the cells for real-time PCR analysis and the cell culture supernatant was analyzed for NGF protein levels using an enzyme linked immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, MN, USA).

Western blotting
To determine the mechanism governing the regulation of NGF by TGF-β, p38 MAPK phosphorylation was examined using western blotting. After stimulation for 30 min as described above, cell lysates were prepared using sodium dodecyl sulfate (SDS) sample buffer. Cell lysates (5 μg) were separated using SDS-polyacrylamide gel electrophoresis before electrophoretic transfer to a polyvinylidene difluoride membrane in blotting buffer. For blocking, the membrane was incubated with 10% nonfat milk in Tris buffered saline containing 0.05% Tween 20 (TBS-T) for 60 min at RT. Subsequently, the membrane was incubated with rabbit polyclonal primary antibodies against p38 MAPK (cat no. 9212; Cell Signaling Technology Japan, Tokyo, Japan) or phospho-p-38 MAPK (Thr180/Tyr182) (cat no. 9211; Cell Signaling Technology Japan) for 1 h at RT, followed by HRP-conjugated goat anti-rabbit IgG antibody for 1 h at RT. The membrane was rinsed 3 times with TBS-T, and
the proteins were visualized by enhanced chemiluminescence using the ImageQuant LAS-4000mini (Fuji Photo Film Co). Bands were analyzed by densitometry using NIH ImageJ software and normalized to p38 expression. Relative p-p38/p-38 expression was determined based on the expression in control samples.

**Statistical analysis**
The relationship between the mRNA expression levels of NGF and TGFβ, TNFA, and IL1B in SYT was analyzed using Spearman’s correlation coefficient. Differences between control- and rhTGF-β-treated cells were analyzed using Bonferroni’s multiple comparisons test. All statistical analyses were performed using Statistical Package for the Social Sciences (SPSS) software (version 25.0, IBM, NY, USA). *P* < 0.05 was used to indicate statistical significant for all analyses.

**Results**

**Correlation between NGF and TGFβ mRNA levels in the SYT of KOA patients**
NGF mRNA levels were positively correlated with those of TGFβ (*ρ* = 0.465, *P* < 0.001; Fig. 1a). In contrast, there was no correlation between NGF and TNFA or IL1B in the SYT (TNFA, *ρ* = 0.049, *P* = 0.616; IL1B, *ρ* = −0.055, *P* = 0.576; Fig. 1b, c).

**Localization of NGF and TGF-β protein in the SYT of KOA patients**
As qPCR analysis detected a correlation between NGF and TGFβ mRNA expression, immunohistochemical analysis was performed to investigate the localization of NGF and TGF-β in SYT. NGF and TGF-β protein were detected in the lining layer of SYT (Fig. 2a, b).

**Effect of an ALK5 inhibitor on TGF-β-induced NGF expression and NGF production in synovial cells**
Flow cytometry demonstrated that cultured synovial cells were primarily made up of CD45-CD90+ fibroblasts (86.3 ± 0.5%, mean ± SE; Additional file 1: Figure S1A) and some CD45 + CD14+ macrophages (8.6 ± 0.6%; Additional file 1: Figure S1B). Stimulation with rhTGF-β increased p38 phosphorylation (*P* = 0.018; Fig. 3a, b) compared to control, and addition of 5 μM SB505124 decreased p38 phosphorylation back to control levels (Fig. 3a, b). Stimulation with exogenous rhTGF-β significantly elevated NGF mRNA levels after 6 and 24 h (*P* < 0.001 and *P* < 0.001, respectively; Fig. 3c), and addition of 5 μM SB505124 completely suppressed this elevation (*P* < 0.001 and *P* < 0.001, respectively; Fig. 3c). Stimulation with exogenous rhTGF-β elevated NGF protein concentrations in the supernatant after 24 h (*P* = 0.001; Fig. 3d), and 5 μM SB505124 completely suppressed this elevation (*P* = 0.001; Fig. 3d).

**Effect of a TAK1 inhibitor on TGF-β-induced NGF mRNA expression and NGF protein production in synovial cells**
Stimulation with rhTGF-β increased p38 phosphorylation (*P* = 0.012; Fig. 4a, b) compared to control, and addition of 1 μM 5Z reduced this increase (*P* = 0.006; Fig. 4a, b). Stimulation with exogenous rhTGF-β significantly elevated NGF mRNA levels after 6 h (*P* = 0.002; Fig. 4c), and addition of 1 μM 5Z significantly reduced this elevation (*P* = 0.002; Fig. 4c). Stimulation with exogenous rhTGF-β also induced an increase in NGF mRNA expression at 24 h (*P* = 0.032; Fig. 4c), while the presence or absence of 1 μM 5Z had no effect on NGF mRNA levels (*P* = 0.107; Fig. 4c). Stimulation with exogenous rhTGF-β elevated NGF protein
concentrations in the supernatant after 24 h ($P = 0.016$; Fig. 4d), and 1 μM 5Z significantly reduced this elevation ($P = 0.017$; Fig. 4d).

**Effect of a p38 inhibitor on TGF-β-induced NGF expression and NGF production in synovial cells**

The increase in rhTGF-β-mediated p38 phosphorylation ($P = 0.045$; Fig. 5a, b) compared to control was reduced by the presence of 1 μM SB203580 (Fig. 5a, b). Similarly, the exogenous rhTGF-β-mediated elevation in NGF mRNA expression after 6 h ($P = 0.001$; Fig. 5c) was significantly reduced by the presence of 1 μM SB203580 ($P = 0.004$; Fig. 5c). Further, the exogenous rhTGF-β-mediated elevation in NGF protein concentration in the supernatant after 24 h ($P = 0.011$; Fig. 5d) was significantly reduced by the presence of 1 μM SB203580 ($P = 0.015$; Fig. 5d).

---

**Fig. 2** Immunolocalization of TGF-β and NGF in synovial tissue. Representative micrographs showing NGF (a) and TGF-β (b) protein expression (brown label) in the synovial lining layer. Region enclosed by dotted lines indicates the synovial lining layer. Scale bar = 100 μm

**Fig. 3** Effect of TGF-β and an ALK5 inhibitor on the phosphorylation of p38 MAPK, NGF mRNA expression, and NGF protein production. Western blotting for phosphorylated p38 MAPK (p-p38) (a-b). Synovial cells were exposed to α-MEM (control), 10 ng/mL human recombinant (rh) TGF-β (TGF-β), or 10 ng/mL rhTGF-β + 5 μM SB505124 (TGF-β + SB505124) for 30 min before protein extraction and western blotting. Western blot for p38 and phosphorylated p38 MAPK (p-p38) (a). Bands were analyzed by densitometry using the NIH Image J software and normalized to p38 expression. Relative p-p38/p-38 expression was determined based on the expression in control samples (b). RT-PCR (c) and ELISA (d) for NGF. Synovial cells were exposed to α-MEM (control), 10 ng/mL rhTGF-β (TGF-β), or 10 ng/mL rhTGF-β + 5 μM SB505124 (TGF-β + SB505124) for 6 and 24 h before RT-PCR (c) or ELISA (d). Relative expression was determined based on the expression in control samples. Data indicate mean ± SE (n = 8). *p < 0.05 compared to control. Data indicate mean ± SE (n = 8). *p < 0.05 compared to control.
Discussion

We examined the mechanisms governing NGF regulation in the SYT of KOA patients. Our findings demonstrate a correlation between TGFβ and NGF expression, and both TGF-β and NGF protein were localized to the synovial lining layer. The ALK5 inhibitor completely suppressed NGF mRNA expression, NGF protein expression, and p38 phosphorylation. Stimulation of synovial cells with rhTGF-β increased NGF mRNA expression and NGF protein production, which were partially inhibited by TAK1 and p38 inhibitors. Our results suggest that TGF-β/ALK5 signaling plays an important role in TGF-β-mediated NGF production and that its action may partially occur through inhibition of the TAK1/p38 pathway in the SYT of KOA patients.

Increased NGF levels have been reported in rheumatoid arthritis, spondyloarthritis, and osteoarthritis patients [23, 24]. Ours and other recent studies have demonstrated that stimulation with inflammatory cytokines such as TNF-α and IL-1β enhances NGF production from human and mouse synovial fibroblasts and macrophages in vitro [8, 10, 19, 25]. In the present study, analysis of human osteoarthritic SYT showed that NGF and TGF-β protein were localized to the synovial lining layer and that NGF mRNA levels were correlated with those of TGFβ but not IL1B or TNFA. A previous study reported a significant increase in the number of TNF-α- and IL-1β-producing cells in the synovium of early stage OA patients undergoing arthroscopic surgery compared to the synovium of late stage KOA patients undergoing total knee arthroplasty (TKA) [12]. Our results, based on samples obtained from late stage KOA patients undergoing TKA, suggest that TGF-β may be one of the main regulators of NGF in the synovium of at least late stage KOA patients.

The canonical pathway plays a key role in regulating NGF mRNA expression. ALK5 inhibition suppressed TGF-β-induced NGF expression in a human pancreatic cell line and osteoarthritic chondrocytes [19, 21]. Consistent with these reports, we showed that an ALK5 inhibitor completely suppressed NGF mRNA expression and NGF protein production. These results suggest that the TGF-β/ALK5 pathway is important for NGF production in osteoarthritic synovium.

Several studies have suggested that non-canonical TGF-β pathway may mediate NGF expression via the MAPK pathway [19, 26]. TAK1 partially regulate TGF-β-induced NGF expression in human chondrocytes...
Phosphorylation of p38 MAPK, a downstream target of TAK1, is suggested to underlie the TGF-β-induced NGF expression in human dental pulp cells [26]. In contrast, previous studies have reported crosstalk between the canonical and non-canonical pathways [27, 28]. The ALK5 inhibitor SB505124 inhibits TGF-β-mediated p38 phosphorylation through suppression of the kinase activity of ALK4 and ALK5 [27]. In our study, we found that ALK5 inhibition with SB505124 suppressed TGF-β-mediated p38 phosphorylation in synovial cells. In addition, TGF-β promoted NGF production, which was partially inhibited by TAK1 and p38 inhibitors in synovial cells similar to previous report describing human cartilages [19]. This evidence suggests that TGF-β/ALK5 signaling-mediated NGF production may be partially regulated by the TAK1/p38 pathway in the SYT of KOA patients. Tanezumab is also generally well tolerated with minor adverse effects [29]. While we did not examine the relationship between NGF mRNA levels and pain in KOA patients, our findings regarding the regulation of NGF by TGF-β in SYT may be important for the development of future treatments for pain associated with KOA.

Conclusions
TGF-β regulates NGF production via the TGF-β/ALK5 signaling pathway in osteoarthritic synovium. This effect may be partially due to inhibition of the TAK1/p38 pathway in the SYT of KOA patients. Our findings may be important for the development of future treatments for pain associated with KOA.

Additional file

Additional file 1: Figure S1. Flow cytometric analysis of cultured synovial cells. Dot-plot analysis of CD90 + CD45− (A) and CD14 + CD45+ (B) cells in synovial cell culture. (TIFF 870 kb)

Abbreviations
APC: Allophycocyanin; BMI: Body mass index; FITC: Fluorescein isothiocyanate; IRB: Institutional review board; K/L: Kellgren/Lawrence; KOA: Knee osteoarthritis; NGF: Nerve growth factor; NSAIDs: Nonsteroidal anti-inflammatory drugs; TGF-β: Transforming growth factor-β; SYT: Synovial lining tissue; TAK1: Transforming growth factor-β activated kinase 1; TAK2: Transforming growth factor-β activated kinase 2; TAK4: Transforming growth factor-β activated kinase 4; TAK5: Transforming growth factor-β activated kinase 5; TGF-β: Transforming growth factor-β.
anti-inflammatory drugs; OA: Osteoarthritis; PE: Phycoerythrin; SDS: Sodium dodecyl sulfate; SE: Standard error; SYT: Synovial tissue; TGF-β: Transforming growth factor-β; TβRRII: TGF-β type I receptor; TβRRII: TGF-β type II receptor.

Acknowledgements
We thank Ms. Yuko Onuki for her assistance with real time PCR analysis.

Funding
This investigation was supported in part by a grant from Japan Orthopaedics and the Traumatology Research Foundation, Inc. No. 373; JSPS KAKENHI Grant No. 18K09119; and research grants from the Parents’ Association of Kitasato University School of Medicine.

Availability of data and materials
The datasets supporting the conclusions of this article are included within the article. The raw data can be requested from the corresponding author.

Authors’ contributions
ST, KU and MT designed the study and analysed the data. ST and KU wrote the manuscript. ST, MI, DI, JA, GI, MM (MukaI), MM (Miyagi), KA, and H5 participated in the data collection, analysis, and interpretation. All authors read and approved the final manuscript.

Ethics approval and consent to participate
This study was approved by the Ethics Review Board of Kitasato University (reference number: KMEO B13-113). Written consent to participate was obtained from all participants for the harvesting of their synovial tissue for use in this study.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Orthopedic Surgery, Kitasato University School of Medicine, 1-15-1 Minami-ku, Kitasato, Sagamihara City, Kanagawa 252-0374, Japan.
2Department of Biochemistry, Kitasato University School of Medicine, 1-15-1 Minami-ku, Kitasato, Sagamihara City, Kanagawa 252-0374, Japan. 3Shonan University of Medical Sciences Research Institute, Nishikubo 500, Chigasaki City, Kanagawa 253-0083, Japan.

Received: 10 August 2018 Accepted: 26 April 2019
Published online: 10 May 2019

References
1. Neogi T. The epidemiology and impact of pain in osteoarthritis. OsteoarthritisCartilage. 2015;23(8):145–53.
2. Bhala N, Emberson J, Mehi A, Abramson S, Arber N, Baron JA, Bombardier C, Cannon C, Farkouh ME, FitzGerald GA, Goss P, Halls H, Hawk E, Hawkey C, Hennekens C, Hochberg M, Holland LE, Kearney PM, Laine L, Lanas A, Lancer P, Laupacis P, Lees J, Patrono C, Schnitzer TJ, Solomon S, Tugwell P, Wilson K, Wittes J, Baigent C. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769–79.
3. Mantyh PW, Koltenbourg M, Mendell LM, Tive L, Shelton DL. Antagonism of nerve growth factor-TrkA signalling and the relief of pain. Anesthesiology. 2011;115(5):189–204.
4. Brown MT, Murphy FT, Radin DM, Davignon J, Smith MD, West CR. Tanezumab reduces osteoarthritis knee pain: results of a randomized, double-blind, placebo-controlled phase III trial. J Pain. 2012;13(8):790–8.
5. Elkan EF, Gimbel JS, Bello AE, Smith MD, Keller DS, Annis KM, Brown MT, West CR, Verboum KG. Efficacy and safety of intravenous tanezumab for the symptomatic treatment of osteoarthritis: 2 randomized controlled trials versus naproxen. J Rheumatol. 2014;41(11):2249–59.
6. Lane NE, Schnitzer TJ, Burbara CA, Mokhtarian M, Shelton DL, Smith MD, Brown MT. Tanezumab for the treatment of pain from osteoarthritis of the knee. NEnglJ Med. 2010;363(16):1521–31.
7. Nagashima H, Suzuki M, Araki S, Yamabe T, Muto C. Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebo-controlled study. Osteoarthritis Cartilage. 2011;19(12):1405–12.
8. Manni L, Lundeberg T, Fiorito S, Bonini S, Vigneti E, Aloe L. Nerve growth factor release by human synovial fibroblasts prior to and following exposure to tumor necrosis factor-alpha, interleukin-1 beta and cholecystokinin-8: the possible role of NGF in the inflammatory response. Clin Exp.Rheumatol. 2003;21(5):167–24.
9. Pecchi E, Priam S, Gosset M, Pigenet A, Sadue L, Laiguillon MC, Berenbaum F, Houard X. Induction of nerve growth factor expression and release by mechanical and inflammatory stimuli in chondrocytes: possible involvement in osteoarthritis pain. Arthritis Res.Ther. 2014;16(1):R16.
10. Takano S, Uchida K, Miyagi M, Inoue G, Fujimaki H, Aikawa J, Iwase D, Minatani A, Iwabuchi K, Takaso M. Nerve growth factor regulation by TGF-α and IL-1beta in synovial macrophages and fibroblasts in osteoarthritic mice. J Immunol. 2016;2016:5706359.
11. Takano S, Uchida K, Miyagi M, Inoue G, Aikawa J, Fujimaki H, Minatani A, Sato M, Iwabuchi K, Takaso M. Synovial macrophage-derived IL-1beta regulates the calcitonin receptor in osteoarthritic mice. Clin Exp Immunol. 2016;2016(3):143–9.
12. Benito MJ, Veale DJ, FitzGerald G, van den Berg WB, Bresnihan B. Synovial tissue inflammation in early and late osteoarthritis. Ann Rheum Dis. 2005;64(9):1263–7.
13. McNamee KE, Burleigh A, Gompels LL, Feldmann M, Allen SJ, Williams RO, Dawbarn D, Vincent TL, Inglis JJ. Treatment of murine osteoarthritis with TGF-α5 reveals a pivotal role for nerve growth factor in non-inflammatory joint pain. Pain. 2010;149(2):386–92.
14. Brodie C. Differential effects of Th1 and Th2 derived cytokines on NGF synthesis by mouse astrocytes. FEBS Lett. 1996;394(2):117–20.
15. Ding J, Niu X, Su Y, Li X. Expression of synovial fluid biomarkers in patients with knee osteoarthritis and meniscus injury. Exp Ther Med. 2017;14(2):1609–13.
16. Lanston S, Englund M, Struligs L, Ahrlander LS. Interleukin-6 and tumor necrosis factor alpha in synovial fluid are associated with progression of radiographic knee osteoarthritis in subjects with previous meniscus injury. Osteoarthritis Cartilage. 2015;23(11):1906–14.
17. Lotz M, Kejow K, Carson DA. Transforming growth factor-beta and cellular immune responses in synovial fluids. J Immunol. 1990;144(11):4899–94.
18. Schlack JF, Pfers I, Meyer Zum Buschenfelde KH, Marker-Hermann E. Different cytokine profiles in the synovial fluid of patients with osteoarthritis, rheumatoid arthritis and seronegative spondylarthropathies. Clin Exp Rheumatol. 1996;14(2):155–62.
19. Blaney Davidson EN, van Caam AP, Vitters EL, Bennink MB, Thijssen E, van den Berg WB, Koenders MI, van Lent PL, van de Loo FA, van der Kraan PM. TGF-beta is a potent inducer of nerve growth factor in articular cartilage via the TGF-Smad-3 pathway. Potential role in OA related pain? Osteoarthritis Cartilage. 2015;23(3):478–86.
20. Miyazawa K, Shinzaki M, Hara T, Furuya T, Miyazono K. Two major Smad pathways in TGF-beta superfamily signalling. Genes Cells. 2002;7(12):1191–204.
21. Haas SL, Fitzner B, Jaster R, Wiercinska E, Gaitantzis H, Jesnowski R, Lohr JM, Singer MW, Dooley S, Breitkopf K. Transforming growth factor-beta induces nerve growth factor expression in pancreatic stellate cells by activation of the ALK-5 pathway. Growth Factors. 2009;27(3):289–99.
22. Minatani A, Uchida K, Inoue G, Takaso S, Aikawa J, Miyagi M, Fujimaki H, Iwase D, Onuma K, Matsumoto T, Takaso M. Activation of calcitonin gene-related peptide signaling through the prostanoid E2/EP1/EP2/EP4 receptor pathway in synovium of knee osteoarthritis patients. J Orthop Surg Res. 2016;11(1):17.
23. Barthel C, Yeremenko N, Jacobs R, Schmidt RE, Bernardzek M, Zeidler H, Tak PP, Baeten D, Rihl M. Nerve growth factor and receptor expression in rheumatoid arthritis and spondyloarthritis. Arthritis Res Ther. 2009;11(3):R82.
24. Montagnoli C, Tribuzi R, Crispolti L, Pizzutti A, Stabile AM, Manfreda F, Placella G, Rende M, Cerrulli GG. Beta-NGF and beta-NGF receptor upregulation in blood and synovial fluid in osteoarthritis. Biol Chem. 2017;398(9):1045–54.
25. Takano S, Uchida K, Inoue G, Miyagi M, Aikawa J, Iwase D, Iwabuchi K, Matsumoto T, Satoh M, Mukai M, Minatani A, Takaso M. Nerve growth factor regulation and production by macrophages in osteoarthritic synovium. Clin Exp Immunol. 2017;190(2):235–43.

26. Yongchaitrakul T, Pavasant P. Transforming growth factor-beta1 up-regulates the expression of nerve growth factor through mitogen-activated protein kinase signaling pathways in dental pulp cells. Eur J Oral Sci. 2007; 115(1):57–63.

27. DaCosta BS, Major C, Laping NJ, Roberts AB. SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7. Mol Pharmacol. 2004;65(3):744–52.

28. Kim H, Kei K, Sonn JK. Staurosporine induces chondrogenesis of chick embryo wing bud mesenchyme in monolayer cultures through canonical and non-canonical TGF-beta pathways. In Vitro Cell Dev Biol Anim. 2016;52(1):120–9.

29. Chen J, Li J, Li R, Wang H, Yang J, Xu J, Zha Z. Efficacy and safety of Tanezumab on osteoarthritis knee and hip pains: a meta-analysis of randomized controlled trials. Pain Med. 2017;18(2):374–85.